|Dr. Geoffrey W. Guy BSc, MB BS, MRCS Eng, LRCP, LMSSA. Dip Pharm Med||Founder and Exec. Chairman||N/A||N/A||63|
|Mr. Justin D. Gover BSc, MBA||Chief Exec. Officer and Exec. Director||N/A||N/A||46|
|Mr. Christopher John Tovey BSc||Chief Operating Officer||N/A||N/A||52|
|Mr. Adam David George BSc, ACA||Managing Director of UK and Sec.||N/A||N/A||47|
|Mr. Julian S. Gangolli||Pres of North America||466.8k||N/A||59|
GW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. It operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. The company markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. It is also developing Sativex in Phase II trials in neuropathic pain. In addition, the companys product pipeline includes Epidiolex, which is in Phase III clinical development for the treatment of dravet syndrome, lennox-gastaut syndrome, tuberous sclerosis complex, and infantile spasms, as well as other product candidates in Phase I and II clinical development for the treatment of glioma, adult epilepsy, and schizophrenia. It primarily operates Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.
GW Pharmaceuticals plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.